AQR Capital Management
TRDA icon

AQR Capital Management’s Entrada Therapeutics TRDA Stock Holding History

AQR Capital Management’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.15M Buy
699,537
+620,044
+780% +$5.95M ﹤0.01% 1983
2026
Q1 		$1M Buy
79,493
+53,239
+203% +$610K ﹤0.01% 2769
2025
Q4 		$270K Buy
26,254
+12,263
+88% +$103K ﹤0.01% 3218
2025
Q3 		$81.1K Sell
13,991
-21,629
-61% -$127K ﹤0.01% 3388
2025
Q2 		$239K Buy
35,620
+4,701
+15% +$37.8K ﹤0.01% 2968
2025
Q1 		$280K Sell
30,919
-24,060
-44% -$300K ﹤0.01% 2722
2024
Q4 		$951K Buy
54,979
+15,511
+39% +$281K ﹤0.01% 1911
2024
Q3 		$631K Buy
+39,468
New +$622K ﹤0.01% 2066

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

AQR Capital Management's TRDA Position: Q2 2026 in Review

AQR Capital Management increased its Entrada Therapeutics (TRDA) stake by 780% in Q2 2026, buying an estimated $5.95M and bringing the position to 699,537 shares worth $5.15M. The position accounts for ﹤0.01% of the portfolio, ranked #1983.

AQR Capital Management first reported a position in TRDA in Q3 2024 and has held it in 8 quarters since. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • AQR Capital Management held 699,537 shares of Entrada Therapeutics worth $5.15M as of Q2 2026.
  • AQR Capital Management bought 620,044 Entrada Therapeutics shares in Q2 2026, an estimated $5.95M.
  • Entrada Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #1983 holding.
  • AQR Capital Management first reported a position in Entrada Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.